Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy
Open Access
- 27 November 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (3) , 3341-3356
Abstract
Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapyKeywords
This publication has 73 references indexed in Scilit:
- Effects of hypoxia on human cancer cell line chemosensitivityBMC Cancer, 2013
- Long‐term Survival in Hilar Cholangiocarcinoma also Possible in Unresectable PatientsWorld Journal of Surgery, 2012
- High-resolution genome-wide mapping of HIF-binding sites by ChIP-seqBlood, 2011
- Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironmentThrombosis Research, 2010
- Targeting the 90 kDa heat shock protein improves photodynamic therapyCancer Letters, 2010
- Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancerHead & Neck Oncology, 2009
- RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularizationProceedings of the National Academy of Sciences, 2009
- Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR dataNucleic Acids Research, 2009
- Regulation of Plasminogen Activator Inhibitor-1 Expression by Tumor Suppressor Protein p53Journal of Biological Chemistry, 2008
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006